Abacavir

CLINICAL USE

Nucleoside reverse transcriptase inhibitor:

Used for HIV infection in combination with other antiretroviral drugs

DOSE IN NORMAL RENAL FUNCTION

600 mg daily in 1 or 2 divided doses

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :(daltons)286.3 (670.7 as sulphate)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :49

%Excreted unchanged in urine &nbsp &nbsp : 2

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.8

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1.5/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux &nbsp : Not dialysed. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp: Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs Antivirals: concentration reduced by tipranavir

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

Tags: post-by-auto-php